research use only

Avanafil PDE inhibitor

Cat.No.S4019

Avanafil is a highly selective PDE5 inhibitor with IC50 of 5.2 nM, >121-fold selectivity over other PDEs.
Avanafil PDE inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 483.95

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 483.95 Formula

C23H26ClN7O3

Storage (From the date of receipt)
CAS No. 330784-47-9 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl

Solubility

In vitro
Batch:

DMSO : 97 mg/mL ( (200.43 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features
Highly selective for PDE5.
Targets/IC50/Ki
PDE5 [1]
1 nM
In vivo
Avanafil (i.v.) potentiates penile tumescence with ED200% of 37.5 μg/kg in dogs. Furthermore, intraduodenal treatment of this compound potentiates pelvic nerve stimulation induced changes in intracavernous pressure and duration. [1] The cavernous injection of this chemical (1 μM) in T2DM rats results in partial improvement in erectile responses. [2]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04374994 Completed
Erectile Dysfunction
University of Alexandria
September 1 2018 Phase 4
NCT01095601 Completed
Healthy
VIVUS LLC
April 2010 Phase 1
NCT01117038 Completed
Erectile Dysfunction
VIVUS LLC
April 2010 Phase 1
NCT01054430 Completed
Erectile Dysfunction
VIVUS LLC
January 2010 Phase 1
NCT01054261 Completed
Renal
VIVUS LLC
January 2010 Phase 1
NCT00914511 Completed
Avanfil ADME|Semen Exposure|Sperm Function
VIVUS LLC
May 2009 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map